This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 clinical data
GIOTRIF® is the first targeted therapy to demonstrate a significant 1st-line OS benefit versus chemotherapy in del19 (exon 19) patients1-3

LUX-Lung 3: Overall survival (secondary endpoint) Preplanned subgroup analysis

LUX-Lung 3: Overall survival (secondary endpoint)
Preplanned subgroup analysis

GIOTRIF® significantly extended 1st-line OS by over 1 year versus pemetrexed/cisplatin in subgroup of del19 patients1

  • 46% reduction in relative risk of death in del19 patients  (HR=0.54; P=0.0015)1
  • In LUX-Lung 3, median OS was 33.3 and 21.1 months for GIOTRIF® versus pemetrexed/cisplatin, respectively (HR=0.54; 95% CI, 0.36–0.79; P=0.0015)1

CI=confidence interval; HR=hazard ratio; OS=overall survival.

LUX-Lung 6 clinical data
GIOTRIF® significantly extended 1st-line OS by over 1 year versus gemcitabine/cisplatin in subgroup of del19 patients1

LUX-Lung 6: Overall survival (secondary endpoint) Preplanned subgroup analysis

LUX-Lung 6: Overall survival (secondary endpoint)
Preplanned subgroup analysis

  • 36% reduction in relative risk of death in del19 patients (HR=0.64; P=0.023)1
  • In LUX-Lung 6, median OS was 31.4 and 18.4 months for GIOTRIF® versus gemcitabine/cisplatin, respectively (HR=0.64; 95% CI, 0.44–0.94; P=0.023)1

CI=confidence interval; HR=hazard ratio; OS=overall survival.

Find out why Sanjay Popat considers LUX-Lung 3 & 6 as valuable!

You may be interested in:

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  2. Fukuoka M et al. J Clin Oncol. 2011;29:2866-2874.
  3. Khozin S et al. Oncologist. 2014;19(7):774-779.
  4. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.
  5. Yang JC et al. Lancet Oncol. 2015;16:830-838.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top